

Liquid Biopsy Market in United States 2022

<https://marketpublishers.com/r/L433C4AC7BA4EN.html>

Date: March 2022

Pages: 13

Price: US\$ 750.00 (Single User License)

ID: L433C4AC7BA4EN

Abstracts

A liquid biopsy is a simple and non-invasive alternative to surgical biopsies which enables doctors to discover a range of information about a tumour through a simple blood sample. Traces of the cancer's DNA in the blood can give clues about which treatments are most likely to work for that patient. According to StrategyHelix, the liquid biopsy market in United States is expected to increase by US\$ 3,801 million during 2022-2028, expanding at a CAGR of 11.7% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for liquid biopsy. The United States liquid biopsy market is segmented on the basis of product, therapy, application, and technology. Based on product, the liquid biopsy market in United States is categorized into kits and reagents, instruments, tests/services. On the basis of therapy, the liquid biopsy market in United States has been segmented into noninvasive prenatal testing (NIPT), oncology, others. By application, the liquid biopsy market in United States has been segmented into therapy guidance, diagnosis/screening, treatment monitoring. Based upon technology, the liquid biopsy market in United States is categorized into NGS, PCR, others.

The United States liquid biopsy market is highly competitive. The liquid biopsy market is dominated by key players, which are Exact Sciences Corp., F. Hoffmann-La Roche AG, Guardant Health Inc., Illumina Inc., Invitae Corp., Laboratory Corporation of America Holdings (Labcorp), Natera Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Sysmex Inostics Inc.

Report Scope

Product: kits and reagents, instruments, tests/services

Therapy: noninvasive prenatal testing (NIPT), oncology, others

Application: therapy guidance, diagnosis/screening, treatment monitoring

Technology: NGS, PCR, others

Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

Get a comprehensive picture of the United States liquid biopsy market

Identify regional strategies and strategic priorities on the basis of local data

Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. LIQUID BIOPSY MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY PRODUCT

Kits and reagents
Instruments
Tests/services

PART 4. MARKET BREAKDOWN BY THERAPY

Noninvasive prenatal testing (NIPT)
Oncology
Others

PART 5. MARKET BREAKDOWN BY APPLICATION

Therapy guidance
Diagnosis/screening
Treatment monitoring

PART 6. MARKET BREAKDOWN BY TECHNOLOGY

NGS
PCR
Others

PART 7. KEY COMPANIES

Exact Sciences Corp.
F. Hoffmann-La Roche AG

Guardant Health, Inc.

Illumina, Inc.

Invitae Corp.

Laboratory Corporation of America Holdings (Labcorp)

Natera, Inc.

QIAGEN N.V.

Quest Diagnostics Incorporated

Sysmex Inostics Inc.

About StrategyHelix

Disclaimer

I would like to order

Product name: Liquid Biopsy Market in United States 2022

Product link: <https://marketpublishers.com/r/L433C4AC7BA4EN.html>

Price: US\$ 750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L433C4AC7BA4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970